[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":244},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,50,73,97,118,138,166,191,215],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100644630","resting-energy-expenditure-in-pediatric-patients-with-inflammatory-bowel-disease-ree-mici-100644630",false,"NCT07670975","Resting Energy Expenditure in Pediatric Patients With Inflammatory Bowel Disease (REE-MICI)","Measurement of Basal Metabolism in Patients With Crohn's Disease and Ulcerative Colitis and Correlation With Disease Activity.","REE-MICI","Inclusion Criteria:\n\n* Pediatric patients aged 6 to 17 years\n* New diagnosis of inflammatory bowel disease, including Crohn disease or ulcerative colitis, according to ECCO\u002FESPGHAN criteria\n* Written informed consent signed by parents or legal guardians\n\nExclusion Criteria:\n\n* Intestinal surgery within 6 weeks before the first evaluation\n* Parenteral or enteral nutrition within 6 weeks before the first evaluation\n* Eating disorders or other chronic diseases associated with possible malabsorption","ALL","6 Years","17 Years",{"count":21,"type":22},50,"ESTIMATED","OBSERVATIONAL","This multicenter prospective observational non-pharmacological study aims to evaluate resting energy expenditure (REE) in pediatric patients affected by inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. REE will be measured using indirect calorimetry and estimated using predictive equations. The study also aims to investigate the relationship between REE, disease activity, and dietary or pharmacological treatments. Clinical, laboratory, anthropometric, nutritional, and disease activity data will be collected during routine clinical follow-up at diagnosis, after induction therapy, and during follow-up visits.",[26,27,28],"Crohn Disease Colitis","Colitis, Ulcerative","Inflammatory Bowel Diseases",[30,31,32,33,34,35,36],"Energy Metabolism","Calorimetry, Indirect","Malnutrition","Pediatric Obesity","Nutritional Status","Child","Disease Activity","RECRUITING","2026-06-22",{"date":40,"type":41},"2026-06-26","ACTUAL",{"date":43,"type":41},"2025-05-01",{"date":45,"type":22},"2027-11",{"name":47,"class":48},"Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":17,"minAge":59,"maxAge":19,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":49},"100644521","epidemiological-evaluation-of-chronic-kidney-disease-in-pediatric-patients-with-inflammatory-bowel-disease-100644521","NCT07670988","Epidemiological Evaluation Of Chronic Kidney Disease In Pediatric Patients With Inflammatory Bowel Disease","A Multicenter, Cross-sectional Observational Study for the Epidemiological Evaluation of Chronic Kidney Disease in Pediatric Patients With Inflammatory Bowel Disease, and Its Relationship With Disease Activity and Medical Therapy.","KIBD","Inclusion Criteria:\n\n* Pediatric patients aged between 2 and 17 years\n* For the case group: confirmed diagnosis of inflammatory bowel disease according to Porto criteria\n* For the control group: absence of current or previous diagnosis of inflammatory bowel disease\n* Availability of clinical and laboratory data required for study evaluation\n* Written informed consent from parent or legal guardian, and assent from the minor when applicable\n\nExclusion Criteria:\n\n* History of pre-existing renal disease (congenital or acquired before IBD diagnosis)\n* Presence of conditions that may affect renal function (e.g., diabetes mellitus, hypertension, chronic use of nephrotoxic drugs)\n* Lack of informed consent",true,"2 Years",{"count":61,"type":22},600,"This multicenter observational cross-sectional study aims to evaluate the prevalence of chronic kidney disease (CKD) in pediatric patients with inflammatory bowel disease (IBD) and to compare it with a control group without IBD.\n\nInflammatory bowel diseases, including Crohn's disease and ulcerative colitis, are chronic conditions that can also affect organs outside the intestine. Among these, kidney involvement has been reported, but data in pediatric populations are limited.\n\nThe study will collect clinical, laboratory, and demographic data from pediatric patients with IBD and matched controls without IBD. The main objective is to estimate the prevalence of CKD in children with IBD and compare it with that observed in the control group. Secondary objectives include describing patient characteristics and exploring potential associations between CKD, disease activity, and medical therapies.\n\nThe results of this study may improve the understanding of kidney complications in pediatric IBD and support earlier diagnosis and better clinical management.",[64],"Inflammatory Bowel Diseases (IBD)",[66],"Pediatric IBD",{"date":40,"type":41},{"date":69,"type":22},"2026-09-01",{"date":71,"type":22},"2027-01",{"name":47,"class":48},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":49},"100538856","mechanical-ventilation-in-surgical-patients-100538856","NCT06296277","Mechanical Ventilation in Surgical Patients","Management of Mechanical Ventilation During Surgery: an International, Multicenter, and Observational Data Registry","MEET VENUS","Inclusion Criteria:\n\n* Adults; and\n* Receiving intraoperative IMV (via tracheal intubation, or supraglottic device ) during general anesthesia for surgery\n\nExclusion Criteria:\n\n* Receiving intraoperative IMV outside of an operating room; and\n* Receiving intraoperative IMV during extracorporeal life support","18 Years",{"count":83,"type":22},10000,"This is an investigator-initiated, international, multicenter, prospective, cross-sectional study that aims to 1) describe the incidence and types of postoperative pulmonary complications (PPCs), 2) describe patient demographics, baseline characteristics, and intraoperative ventilation management, 3) describe the occurrence of intraoperative adverse events (IAEs), and 4) their associations with PPCs, 5) assess the practice of intraoperative mechanical ventilation.\n\nPatients will be eligible for participation if: 1) adult and 2) receiving intraoperative ventilation during general anesthesia for surgery. Patients receiving ventilation outside of an operating room as well as patients receiving intraoperative ventilation during extracorporeal life support will be excluded",[86,87,88],"Surgery","Ventilator Lung","Postoperative Complications","2026-05-25",{"date":91,"type":41},"2026-05-28",{"date":93,"type":41},"2026-03-01",{"date":95,"type":22},"2027-08-31",{"name":47,"class":48},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":49},"100613925","comparison-of-the-resection-site-order-in-simultaneous-approach-of-colorectal-liver-metastasis-100613925","NCT07272928","Comparison of the Resection Site Order in Simultaneous Approach of Colorectal Liver Metastasis","Comparison of the Resection Site Order in Simultaneous Approach of Colorectal Liver Metastasis. An International Multicentric Retrospective Trial.","CORSICO","Inclusion Criteria:\n\n* Adult patients diagnosed with colorectal cancer with synchronous liver metastases during the reference period, who underwent simultaneous resection.\n\nExclusion Criteria:\n\n* Simultaneous emergency resection due to symptoms of the primary tumor.\n* Presence of extrahepatic metastatic disease confirmed at the time of resection or diagnosis.\n* High surgical risk defined as an ASA risk score greater than 3.\n* At least 10 cases performed by the invited center during the study period.\n* Incomplete data or follow-up of less than 6 months.",{"count":106,"type":22},500,"Colorectal cancer frequently presents with liver metastases, and complete removal of both primary and liver tumors can significantly improve survival. Simultaneous resection (SA) of the colon and liver is increasingly used and is considered safe when minor liver resections are performed, offering advantages such as shorter hospitalization, fewer complications, and faster chemotherapy initiation.\n\nHowever, the best sequence of resection, liver-first or colon-first, remains uncertain, as each has potential benefits and drawbacks, particularly regarding anastomotic healing. Minimally invasive approaches to SA show similar outcomes to open surgery, though limited data suggest that resection order may affect blood loss.",[109],"Colorectal Liver Metastasis","2025-11-26",{"date":112,"type":41},"2025-12-09",{"date":114,"type":41},"2025-02-27",{"date":116,"type":22},"2026-08-27",{"name":47,"class":48},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":49},"100612322","pretreatment-mri-for-occult-liver-metastasis-assessment-in-pancreatic-ductal-adenocarcinoma-100612322","NCT07252076","PRetreatment MRI for OCcult Liver Metastasis Assessment In Pancreatic Ductal adenocarcinoMa","PRetreatment MRI for OCcult Liver Metastasis Assessment In Pancreatic Ductal adenocarcinoMa. An International Multicentric, Prospective, Diagnostic Accuracy Trial","PROCLAIM","Inclusion Criteria:\n\n* Male or female patients over 18 years of age.\n* Patients with a new cytological or histological diagnosis of PDAC.\n* A CT scan demonstrating pancreatic disease and meeting the minimum criteria for the imaging assessment of pancreatic gland tumors (see section 4.6, study procedures).\n* An MRI performed no later than 3 weeks after the CT scan, also meeting the minimum radiological criteria (see section 4.6, study procedures).\n* No prior treatment for pancreatic disease.\n* Patients able to receive and understand the study information and to provide written informed consent duly signed by both the patient and the investigator.\n\nExclusion Criteria:\n\n* Signs of metastatic disease on the initial CT scan (hepatic, pulmonary, distant lymph node, peritoneal carcinomatosis, or other organ involvement).",{"count":127,"type":22},120,"Pancreatic cancer has a low survival rate largely due to late diagnosis and undetected liver metastases. Computed tomography (CT), the standard diagnostic tool, often misses occult metastases that are later discovered during surgery. Recent studies suggest that magnetic resonance imaging (MRI), especially with diffusion-weighted imaging (DWI), can better detect very small liver metastases and help avoid unnecessary surgery. However, MRI is not yet widely used in routine practice due to limited evidence and its selective application. This study proposes incorporating contrast-enhanced MRI and DWI into the diagnostic workflow to improve diagnostic accuracy and guide more effective treatment decisions for patients with pancreatic cancer.",[130],"Pancreatic Ductal Adenocarcinoma","2025-11-19",{"date":110,"type":41},{"date":134,"type":41},"2025-07-17",{"date":136,"type":22},"2027-01-17",{"name":47,"class":48},{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":148,"phases":149,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":49},"100589871","procalcitonin-aided-antimicrobial-therapy-vs-standard-of-care-100589871","NCT06960044","Procalcitonin Aided Antimicrobial Therapy vs Standard of Care","Procalcitonin Aided Antimicrobial Therapy vs Standard of Care: a Randomized Prospective Clinical Trial","PCT","Inclusion Criteria:\n\n* age ≥18 years;\n* clinical and instrumental diagnosis of LRTI consistent with bacterial origin and requiring antimicrobial treatment;\n* patient hospitalized in Internal Medicine, Geriatrics, Infectious Disease unit, Pneumology, Semi Intensive Care unit, ICU, Emergency Medicine;\n* informed consent provided by the patient.\n\nExclusion Criteria:\n\n* age \\\u003C 18 years;\n* lack of informed consent;\n* severe immunosuppression (other than related to corticosteroid use);\n* concomitant diagnosis of other infections requiring long term antimicrobial therapy (i.e. endocarditis, osteomyelitis)",{"count":147,"type":22},108,"INTERVENTIONAL",[150],"NA","Antibiotic resistance is driven by overuse, especially for viral respiratory infections. Procalcitonin (PCT), a biomarker for bacterial infections, helps guide antibiotic therapy more precisely, reducing unnecessary use and improving outcomes. Studies, including large trials and economic models across several countries, show PCT-guided treatment lowers mortality, antibiotic exposure, therapy duration and related complications, potentially reducing hospital costs despite initial testing expenses.",[153],"Lower Respiratory Tract Infection (LRTI)",[155,156],"procalcitonin","procalcitonin-guided antibiotic management","NOT_YET_RECRUITING","2025-05-05",{"date":160,"type":41},"2025-05-07",{"date":162,"type":22},"2025-06-01",{"date":164,"type":22},"2027-06-01",{"name":47,"class":48},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":148,"phases":176,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":49},"100589247","evaluation-of-the-impact-of-medium-chain-fatty-acids-in-the-evolution-of-newly-diagnosed-mild-cognitive-impairment-100589247","NCT06951932","Evaluation of the Impact of Medium-chain Fatty Acids in the Evolution of Newly Diagnosed Mild Cognitive Impairment","Evaluation of the Impact of Medium-chain Fatty Acids in the Evolution of Newly Diagnosed Mild Cognitive Impairment: Prospective Randomized Controlled Trial","MCI-MCT","Inclusion Criteria:\n\n* Age between 18 and 85 years;\n* Diagnosis of MCI;\n* Disease duration of less than 24 months from symptom onset;\n* Absence of malnutrition (diagnosed according to the NRS 2002 screening test) and with oral intakes sufficient to cover energy requirements (calculated by the Harris-Benedict formula, adjusted for activity factor and pathology);\n* Ability to understand and sign informed consent.\n\nExclusion Criteria:\n\n* Patients on total or supplemental enteral nutrition\n* Severe dysphagia\n* Patients with glycated hemoglobin \\> 8%\n* Patients on insulin therapy\n* Patients with poor beta-cell function (e.g., pancreasectomy, acute and chronic pancreatitis)\n* Patients with liver failure: MELD score \\> 9\n* Malnutrition (diagnosed according to the NRS 2002 screening test) and with per os intakes \\\u003C 60% of energy requirements (calculated using the Harris-Benedict formula, corrected for activity factor and pathology)\n* Metabolic disorders and\u002For enzyme disorders, dyslipidemia with total cholesterolemia \\>300 mg\u002Fdl and\u002For triglyceridemia \\>400 mg\u002Fdl)\n* Acute inflammatory disease or ongoing or recent (within 30 days) infectious states\n* Hypo- and hyperthyroidism not adequately compensated by treatment\n* Heart failure (NYHA III-IV), unstable angina, recent (\\\u003C6 months) acute cardiovascular or cerebrovascular events\n* Pregnancy or lactation\n* Neurological disorders other than MCI, psychiatric disorders\n* Nutrition and eating disorder\n* Alcohol abuse\n* Institutionalized patients\n* Participation in experimental therapies in the 2 months prior to enrollment\n* Allergy to MCT oil, nuts","85 Years",{"count":127,"type":22},[150],"Mild cognitive impairment (MCI) is considered the intermediate stage between the changes observed in physiological aging and dementia. Currently, there is no drug therapy, and available drugs offer only minimal benefit on symptoms, only partially slowing the course of the condition. Studies in the literature have investigated the role of omega-3 fatty acids in MCI, and when administered over a period of six months, they appear to improve clinical condition and mood. In addition, medium-chain triglycerides (MCTs) appear to exert an antioxidant function, enhance cognitive ability in patients with MCI or Alzheimer's, and promote deep sleep state.",[179],"Mild Cognitive Impairment (MCI)",[181,182],"Montreal Cognitive Assessment","medium-chain triglycerides","2025-04-30",{"date":185,"type":41},"2025-05-04",{"date":187,"type":41},"2024-07-03",{"date":189,"type":22},"2025-11-03",{"name":47,"class":48},{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":198,"targetDuration":199,"studyType":23,"phases":4,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":49},"100570462","italian-data-registry-of-patients-undergoing-peripheral-nerve-block-performed-in-the-emergency-departments-100570462","NCT06707558","Italian Data Registry of Patients Undergoing Peripheral Nerve Block Performed in the Emergency Departments","ED-RA","Inclusion Criteria:\n\n* Age ≥18 years;\n* NRS\\>3\n* Patients with traumatic fractures of ≤2 districts (radiologically confirmed (RX or CT). Districts are:\n\nChest (one hemilateral) Pelvis (one hemilateral) Femur Leg Ankle Foot Shoulder Humerus Forearm Hand\u002Ffingers\n\n\\- Presence of written informed consent to the study.\n\nExclusion Criteria:\n\n* Intubated patients\n* Patients with known dementia\n* Patients with delirium (assessed by Confusion Assessment Method)\n* Pregnant patients\n* Patients with allergies to local anesthetics\n* Patients unable to adequately communicate pain",{"count":106,"type":22},"7 Days","This data registry aim is to describe the practice of Point-of-Care Ultrasound Guided Regional Anaesthesia (POCUS-GRA) in emergency departments of nosocomial hospitals where, the organizational structure, has already provided for the implementation of peripheral nerve blocks (PNB) in common clinical practice for the treatment of acute pain due to bone fractures.",[202,203,204,205,206],"Emergency","Point of Care Ultrasound (POCUS)","Anesthesia","Acute Pain","Trauma","2024-11-26",{"date":209,"type":41},"2024-11-29",{"date":211,"type":22},"2024-12-10",{"date":213,"type":22},"2025-12-31",{"name":47,"class":48},{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":148,"phases":225,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":243},"100321524","timing-to-minimally-invasive-surgery-after-neoadjuvant-chemoradiotherapy-for-rectal-cancer-100321524","NCT03465982","Timing to Minimally Invasive Surgery After Neoadjuvant Chemoradiotherapy for Rectal Cancer","Timing to Minimally Invasive Surgery After Neoadjuvant Chemoradiotherapy for Rectal Cancer: a Multicenter Randomised Controlled Trial","TiMiSNAR","Inclusion Criteria:\n\n* Age \\>18 years\n* cT3\u002F4N0\u002F+M0 confirmed on CT-scan, MRI (stratification for T3a-b-c-d) 3\n* Tumor starting from the distal or medium rectum (even those crossing the peritoneal reflection at distal margin, within 15 cm from the anal margin)\n* Histologically-proven adenocarcinoma of the rectum\n* Eligible for a resective surgery with TME (low anterior resection, intersphincteric resection, abdominoperineal resection)\n* Eligible for resection by minimally-invasive surgery (standard or robotic-assisted laparoscopic procedure, all robotic systems will be accepted)\n* Eligible for chemoradiation treatment\n* Able to give written informed consent\n* Capable of completing required questionnaires at time of consent (provided questionnaires are available in a language spoke fluently by the participant)\n\nExclusion Criteria:\n\n* Metastatic disease\n* Squamous carcinoma of the anal canal\n* Synchronous colorectal tumors requiring multi-segment surgical resection (n.b. a benign lesion within the resection field in addition to the main cancer would not exclude a patient)\n* History of psychiatric or addictive disorder or other medical condition that, in the opinion of the investigator, would preclude the patient from meeting the trial requirements\n* Pregnancy\n* Unable to complete neoadjuvant treatment\n* Unable to give free informed consent\n* Previous radiation treatment on the pelvis\n* Inflammatory bowel disease\n* Hereditary colorectal disease\n* Previous tumors other than non-melanoma skin cancer, papillary or follicular thyroid cancer\n* Participation in another rectal cancer clinical trial relating to the topic of this trial",{"count":224,"type":22},340,[150],"The trial is a multicenter, prospective, randomized controlled, unblinded, parallel-group trial comparing standard and delayed surgery after neoadjuvant chemoradiotherapy for the curative treatment of rectal cancer. Three-hundred and thirty-two patients will be randomized on an equal basis to either robotic-assisted\u002Fstandard laparoscopic rectal cancer surgery after 8 weeks or robotic-assisted\u002Fstandard laparoscopic rectal cancer surgery after 12 weeks. The recruiting interval will be of 5 years and the follow-up period will end 5 years after the last patient is randomized.",[228],"Rectal Cancer",[230,231,232,233,234],"rectal cancer","robotic rectal cancer resection","minimally invasive surgery","Colorectal Cancer","chemoradiation treatment rectal cancer","2024-04-15",{"date":237,"type":41},"2024-04-16",{"date":239,"type":41},"2018-06-05",{"date":241,"type":22},"2029-06-05",{"name":47,"class":48},14,""]